In 2002, financial executive Warren Lammert co-founded Epilepsy.com and the Epilepsy Therapy Project following his daughter’s diagnosis with Dravet syndrome, a rare form of epilepsy. Combining his passion for the search for innovative treatments with skills developed over several decades in the finance industry, Warren Lammert most recently co-founded Tevard Biosciences. Tevard is developing gene therapies for Dravet and other poorly treated genetic disorders. Additionally, Warren Lammert serves as chairman of Cerebral Therapeutics, which seeks to develop therapies for epilepsy that can be delivered directly to the central nervous system. He also serves on the board of Engage Therapeutics, a company advancing a fast-acting inhaled rescue therapy for people living with uncontrolled seizures. Currently the CIO of Boston-based Granite Point Capital Management, Warren Lammert is a former board chair and current board member of the Epilepsy Foundation. He was a co-founder of Epilepsy.com and the Epilepsy Therapy Project, both of which now operate under the umbrella of the Epilepsy Foundation. In 2013 the Epilepsy Foundation recognized him for his accomplishments in supporting innovative research at its World Changers Gala. His work in the field has also earned recognition from FACES (Finding a Cure for Epilepsy and Seizures) and the Epilepsy Foundation of New England.